Skip to main content
. 2012 Aug 28;6(8):e1750. doi: 10.1371/journal.pntd.0001750

Figure 1. Industry response to priority review voucher (PRV) influence on decision making.

Figure 1

Companies rated the importance of the PRV on initiating (A) and continuing (B) R&D projects for new neglected tropical disease (NTD) medicines. Responses were identified into “large” companies (>500 FTEs) and “small” companies (<60 FTEs). Note: One small company did not respond to the survey question that supplied the data for (B).